Lambert-Eaton myasthenic syndrome: Search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 145-152

  Takamori, Masaharu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Lambert Eaton myasthenic syndrome; Neurotrophins; Presynaptic calcium homeostasis; Presynaptic muscarinic acetylcholine receptor; Synaptotagmin; Voltage gated calcium channel

Indexed keywords

CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; G PROTEIN COUPLED RECEPTOR; HLA DR3 ANTIGEN; MUSCARINIC M1 RECEPTOR; NEUROTROPHIN; PROTEIN KINASE C; SYNAPTOTAGMIN I; VOLTAGE GATED CALCIUM CHANNEL;

ARTICLE; CALCIUM HOMEOSTASIS; CHOLINERGIC TRANSMISSION; CROSS REACTION; EATON LAMBERT SYNDROME; HUMAN; LUNG SMALL CELL CANCER; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN FUNCTION; SYNAPTIC TRANSMISSION;

ANIMALS; CALCIUM; HOMEOSTASIS; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; MODELS, BIOLOGICAL; PRESYNAPTIC TERMINALS; RECEPTORS, CHOLINERGIC; SYNAPTOTAGMINS;

EID: 51649095015     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.04.040     Document Type: Article

References (63)

1. Anderson H.J., Churchill-Davidson H.C., and Richardson A.T. Bronchial neoplasm with myasthenia. Prolonged apnea after administration of succinylcholine. Lancet 2 (1953) 1291-1293
2. Benatar M., Blaes F., Johnston I., Wilson K., Vincent A., Beeson D., and Lang B. Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. J. Neuroimmunol. 113 (2001) 153-162
3. Cremona O., and De Camilli P. Phosphoinositides in membrane traffic at the synapse. J. Cell Sci. 114 (2001) 1041-1052
4. 2+-phospholipid complex in neurotransmitter. J. Biol. Chem. 367 (2007) 848-863
5. Daly C., Sugimoto M., Moriera J.E., Ziff E.B., and Llinás R. Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. Proc. Natl. Acad. Sci. USA 97 (2000) 6120-6125
6. David P., el Far O., Martin-Mautôt N., Poupon M.E., Takahashi M., and Seagar M.J. Expression of synaptotagmin and syntaxin associated with N-type calcium channels in small cell lung cancer. FEBS Lett. 326 (1993) 135-139
7. el Far O., Marquèze B., Leveque C., Martin-Moutôt N., Lang B., Newsom-Davis J., Yoshida A., Takahashi M., and Seagar M.J. Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome. J. Neurochem. 64 (1995) 1696-1702
8. Elmqvist D., and Lambert E.H. Detailed analysis of neuromuscular transmission in a patient with bronchogenic carcinoma. Mayo Clin. Proc. 43 (1968) 689-713
9. Frank C.A., Kennedy M.J., Goold C.P., Marek K.W., and Davis G.W. Mechanisms underlying the rapid induction and sustained expression of synaptic homeostasis. Neuron 52 (2006) 663-677
10. Fukuda T., Motomura M., Nakao Y., Shiraishi H., Yoshimura T., Iwanaga K., Tsujihata M., and Eguchi K. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann. Neurol. 53 (2003) 21-28
11. Fukunaga H., Engel A.G., Lang B., Newsom-Davis J., and Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc. Natl. Acad. Sci. USA 60 (1983) 7636-7640
12. Garcia N., Santafé M.M., Salon I., Lanuza M.A., and Tomàs J. Expression of muscarinic acetylcholine receptors (M1-, M2-, M3-, and M4-type) in the neuromuscular junction of the newborn and adult rat. Histol. Histopathol. 20 (2005) 733-743
13. Giovannini F., Sher E., Webster R., Boot J., and Lang B. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br. J. Pharmacol. 136 (2002) 1135-1145
14. Hulme E.C., Birdsall N.J.M., and Buckley N.J. Muscarinic receptor subtypes. Ann. Rev. Pharmacol. Toxicol. 30 (1990) 633-673
15. Iwasa K., Takamori M., Komai K., and Mori Y. Recombinant calcium channel is recognized by Lambert-Eaton myasthenic syndrome antibodies. Neurology 54 (2000) 757-759
16. Kim J.Y., and Saffen D. Activation of M1 muscarinic acetylcholine receptors stimulates the formation of a multi-protein complex centered on TRPC6 channels. J. Biol. Chem. 280 (2005) 32035-32047
17. Komai K., Iwasa K., and Takamori M. Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J. Neurol. Sci. 166 (1999) 126-130
18. Lambert E.H., Eaton L.M., and Rooke E.D. Defect of neuromuscular conduction associated with malignant neoplasm. Am. J. Physiol. 187 (1956) 612-613
19. Lang B., Newsom-Davis J., Prior C., and Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J. Physiol. 344 (1983) 335-345
20. Lang B., Newsom-Davis J., Peers C., Prior C., and Wray D. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J. Physiol. 390 (1987) 257-270
21. 2+ influx in tumor cells correlates with disease severity. Ann. Neurol. 25 (1989) 265-271
22. Lang B., Pinto A., Giovannini F., Newsom-Davis J., and Vincent A. Pathogenic autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann. N.Y. Acad. Sci. 998 (2003) 187-195
23. Lennon V.A., Kryzer T.J., Griesmann G., O'suilleabhain P.E., Windebank A.J., Woppmann A., Miljanich G.P., and Lambert E.H. Calcium channel antibodies in the Lambert-Eaton syndrome and other neoplastic syndromes. N. Engl. J. Med. 332 (1995) 1467-1474
24. Maddison P., Newsom-Davis J., Mills K.R., and Souhami R.L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353 (1999) 117-118
25. Martens S., Kozlov M.M., and McMahon T.T. How synaptotagmin promotes membrane fusion. Science 316 (2007) 1205-1208
26. Mason W.P., Graus F., Lang B., Honnorat J., Delattre J.-Y., Valldeoriola F., Antoine J.C., Rosenblum M.K., Rosenfeld M.R., Newsom-Davis J., Posner J.B., and Dalmau J. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120 (1997) 1279-1300
27. Matteorli M., Takei K., Perin M.S., and Südhof T.C. Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons. J. Cell Biol. 117 (1992) 859-861
28. Minic J., Molgo J., Karlsson E., and Krejci E. Regulation of acetylcholine release by muscarinic receptor at the mouse neuromuscular junction depends on the activity of acetylcholinesterase. Eur. J. Neurosci. 15 (2002) 439-448
29. Motomura M., Johnston I., Lang B., Vincent A., and Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry 58 (1995) 85-87
30. Nagel A., Engel A.G., Lang B., Newsom-Davis J., and Fukuoka T. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation. Ann. Neurol. 24 (1988) 552-558
31. Nakao Y., Motomura M., Fukudome T., Fukuda T., Shiraishi H., Yoshimura T., Tsujihata M., and Eguchi K. Seronegative Lambert-Eaton myasthenic syndrome. Study of 110 Japanese patients. Neurology 59 (2002) 1773-1775
32. Nantilla C.B., Zhan W.-Z., and Sieck G.C. Neurotrophins improve neuromuscular transmission in the adult rat diaphragm. Muscle Nerve 29 (2004) 381-386
33. Neves G., Gomis A., and Lagnado L. Calcium influx selects the fast mode of endocytosis in the synaptic terminal of retinal bipolar cells. Proc. Natl. Acad. Sci. USA 98 (2001) 15282-15287
34. Newsom-Davis J. The emerging diversity of neuromuscular junction disorders. Acta Myol. 26 (2007) 5-10
35. Newsom-Davis J., and Murray N.M.F. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34 (1984) 480-485
36. Oguro-Okamoto M., Griesmann G.E., Wieben E.D., Slaymaker S.J., Snutch T.P., and Lennon V.A. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin. Proc. 67 (1992) 1150-1159
37. O'Neill J.H., Murray N.M.F., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 (1988) 577-596
38. Pinto A., Gillard S., Moss F., Whyte K., Brust P., Williams M., Stauderman K., Harpold M., Lang B., Newsom-Davis J., Bleakman D., Lodge D., and Boot J. Human autoantibodies specific for the alpha 1A calcium channel subunit reduces both P-type and Q-type calcium currents in cerebellar neurons. Proc. Natl. Acad. Sci. USA 95 (1998) 8328-8333
39. Pinto A., Iwasa K., Newland C., Newsom-Davis J., and Lang B. The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle Nerve 25 (2002) 715-724
40. Roberts A., Perera S., Lang B., Vincent A., and Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 317 (1985) 737-739
41. Sabater L., Titulaer M., Saiz A., Verschuuren J., Güre A.O., and Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 70 (2008) 924-928
42. Santafé M.M., Lanuza M.A., Garcia N., and Tomàs J. Muscarinic autoreceptors modulate transmitter release through protein kinase C and protein kinase A in the rat motor nerve terminal. Eur. J. Neurosci. 23 (2006) 2048-2056
43. Santafé M.M., Lanuza M.A., Garcia N., Tomàs M., and Tomàs J. Coupling of presynaptic muscarinic autoreceptors to serine kinases in low and high release conditions on the rat motor nerve terminal. Neuroscience 148 (2007) 432-440
44. Sons M.S., Busche N., Strenzke N., Moser T., Ernsberger U., Mooren F.C., Zhang W., Ahmad M., Steffens H., Schomburg E.D., Plomp J.J., and Missler M. Alpha-neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction. Neuroscience 138 (2006) 433-446
45. Stoop R., and Poo M.-M. Synaptic modulation by neurotrophic factors: differential and synergistic effects of brain-derived neurotrophic factor and ciliary neurotrophic factor. J. Neurosci. 16 (1996) 3256-3264
46. Südhof T.C. The synaptic vesicle cycle. Annu. Rev. Neurosci. 27 (2004) 509-547
47. 2+ affinities. EMBO J. 21 (2002) 270-280
48. Takamori M., Gutmann L., Crosby T.W., and Martin J.D. Myasthenic syndromes in hypothyroidism. Electrophysiological study of neuromuscular transmission and muscle contraction in two patients. Arch. Neurol. 26 (1972) 326-335
49. Takamori M., Hamada T., Komai K., Takahashi M., and Yoshida A. Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann. Neurol. 35 (1994) 74-80
50. Takamori M., Takahashi M., Yasukawa Y., Iwasa K., Nemoto Y., Suenaga A., Nagataki S., and Nakamura T. Antibody to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 133 (1995) 95-101
51. Takamori M., Iwasa K., and Komai K. Antibodies to synthetic peptide of the α1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 48 (1997) 1261-1265
52. Takamori M., Maruta T., and Komai K. Lambert-Eaton myasthenic syndrome as an autoimmune calcium channelopathy. Neurosci. Res. 36 (2000) 183-191
53. Takamori M., Motomura M., Fukudome T., and Yoshikawa H. Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders. Eur. J. Neurol. 14 (2007) 1230-1235
54. Tyler W.J., Perrett S.P., and Pozzo-Miller L.D. The role of neurotrophins in neurotransmitter release. Neuroscientist 8 (2002) 524-531
55. Vernino S., Adamski J., Kryzer T.J., Fealey R.D., and Lennon V.A. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndrome. Neurology 50 (1998) 1806-1813
56. Verschuuren J.J., Dalmau J., Tunkel R., Lang B., Graus F., Schramm L., Posner J.R., Newsom-Davis J., and Rosenfeld M.R. Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome. Neurology 50 (1998) 475-479
57. Vincent A., Lang B., and Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 12 (1989) 496-502
58. Vincent A., Leite M.I., Farrugia M.E., Jacob S., Viegas S., Shiraishi H., Benveniste O., Morgan B.P., Hilton-Jones D., Newsom-Davis J., Beeson D., and Willcox N. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann. N.Y. Acad. Sci. 1132 (2008) 84-92
59. Waterman S.A., Lang B., and Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann. Neurol. 42 (1997) 145-156
60. Willcox N., Demaine A.G., Newsom-Davis J., Welsh K.I., Robb S.A., and Spiro S.G. Increased frequency of IgG heavy chain Glm(2) and of HLA-B8 in the Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma. Human Immunol. 14 (1985) 29-36
61. Williams C.J. Muscarinic signaling in carcinoma cells. Life Sci. 72 (2003) 2173-2182
62. Wirtz P.W., Willcox N., van der Slik A.R., Lang B., Maddison P., Koeleman B.P., Giphart M.J., Wintzen A.R., Roep B.O., and Verschuuren J.J. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J. Neuroimmunol. 159 (2005) 230-237
63. 2+ sensors for fast release that specify distinct presynaptic properties in subsets of neurons. Neuron 54 (2007) 567-581